The Effect of Ursodeoxycholic Acid on Biliary Bile Acid Composition in Patients with Cholesterol Gallstone

YOSHIHIKO KANAZAWA, MASARU KOIZUMI, HIDETOSHI HIRAKAWA, KATSUHIRO ENDO, SHIN YOSHIDA, TAKATOSHI MIYAKAWA, YASUTOSHI KONNO, YOSHIO GOTO, JUNICHI GOTO* and TOSHIO NAMBARA*

Third Department of Internal Medicine, Tohoku University School of Medicine, Sendai 980 and *Pharmaceutical Institute, Tohoku University, Sendai 980

KANAZAWA, Y., KOIZUMI, M., HIRAKAWA, H., ENDO, K., YOSHIDA, S., MIYAKAWA, T., KONNO, Y., GOTO, Y., GOTO, J. and NAMBARA, T. The Effect of Ursodeoxycholic Acid on Biliary Bile Acid Composition in Patients with Cholesterol Gallstone. Tohoku J. exp. Med., 1982, 136 (3), 235-249 --- To elucidate the role of conjugated biliary bile acids in gallstone dissolution, the acids in bile were determined by high-performance liquid chromatography before and after the treatment with ursodeoxycholic acid for 3-26 months in patients with gallstone. The stone-dissolving effect of ursodeoxycholic acid was confirmed in 7 of 10 patients and the lithogenic index lowered significantly after the treatment. The compositions of cholate, chenodeoxycholate and ursodeoxycholate were about 33, 45 and 4%, respectively, in the control and pre-treatment groups. In the post-treatment group, a markedly low value was observed in primary bile acids both glycine-conjugates and taurine-conjugates, especially in cholate, with a significantly high value of ursodeoxycholate (p<0.001) of both conjugates. On the other hand, no difference was observed in the composition of deoxycholate with significantly low percentage of taurine-conjugates compared with that in the pre-treatment group. The ratio of glycine- to taurine-conjugated bile acids showed a significantly higher value in the post-treatment group than in the pre-treatment group (p<0.001) and the control group (p<0.005). The bile specimens were measured concomitantly by gas-liquid chromatography and the results were compared with those of high-performance liquid chromatography. The mean value of total bile acids, the ratio of cholate to chenodeoxycholate and the ratio of glycine- to taurine-conjugated bile acids obtained by the former analysis procedure represented about 57, 80 and 115% of those of the latter. It is concluded that the high G/T value seems to have a role in the dissolution mechanism. --- bile acid; ursodeoxycholic acid; cholesterol gallstone; high-performance liquid chromatography; ratio of glycine- to taurine-conjugated bile acids (G/T ratio)

Since the dissolution of cholesterol gallstones by chenodeoxycholic acid (CDCA) (Bell et al. 1972; Danzinger et al. 1972) and ursodeoxycholic acid (UDCA) (Sugata and Shimizu 1974; Makino et al. 1975) was demonstrated, an attention has been

Received for publication, June 15, 1981.

Current methods for the determination of bile acids involve alkaline hydrolysis of the conjugates under drastic conditions followed by gas-liquid chromatographic (GLC) separation of liberated bile acids (Nakayama 1967; Iwabuchi 1978). This procedure, however, has inevitable disadvantages, viz. lack of reliability of the analytical results due to incomplete hydrolysis and formation of artifacts as well as the loss of information about the conjugate form of bile acids.

Recently, many attempts have been made to separate the bile acids by high-performance liquid chromatography (HPLC) without hydrolysis of conjugate form (Goto et al. 1978, 1980). Nevertheless, there have been no reports available on the application of this method for the determination of bile acids in patients with gallstone. The present paper describes the compositions of biliary glycine- and taurine-conjugated bile acids in gallstone patients before and after the administration of ursodeoxycholic acid (UDCA). A comparison of results obtained by GLC and HPLC methods is discussed.

**MATERIALS AND METHODS**

*Subjects*

The subjects consisted of 17 patients, 5 males and 12 females, having asymptomatic radiolucent gallstones in well visualized functioning gallbladders. The age range was from 22 to 78 years. Sixteen patients were administered 600 mg/day of UDCA and one patient 450 mg/day. All patients continued taking their customary diet during the study, and no change in body weight was seen in any patient after the treatment. Table 1 shows the characteristics of 10 patients in whom the clinical effects of UDCA could be followed.

Bile specimens were obtained from 15 patients before, and from 7 patients after the administration of UDCA. In 5 of these patients bile samples were taken before and after the treatment. As the control subjects, 6 healthy volunteers (6 male, aged 18–23)

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Sex</th>
<th>Height (cm)</th>
<th>Weight (kg)</th>
<th>Relative BW (%)</th>
<th>Dose (mg/day)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. K.S.</td>
<td>46</td>
<td>F</td>
<td>154</td>
<td>57</td>
<td>117.5</td>
<td>600</td>
</tr>
<tr>
<td>2. T.A.</td>
<td>63</td>
<td>F</td>
<td>144</td>
<td>41</td>
<td>103.5</td>
<td>600</td>
</tr>
<tr>
<td>3. N.O.</td>
<td>25</td>
<td>F</td>
<td>162</td>
<td>55</td>
<td>98.6</td>
<td>600</td>
</tr>
<tr>
<td>4. L.M.</td>
<td>67</td>
<td>F</td>
<td>152</td>
<td>50</td>
<td>106.8</td>
<td>600</td>
</tr>
<tr>
<td>5. M.M.</td>
<td>61</td>
<td>M</td>
<td>155</td>
<td>51</td>
<td>103.0</td>
<td>600</td>
</tr>
<tr>
<td>6. N.S.</td>
<td>61</td>
<td>M</td>
<td>160</td>
<td>53</td>
<td>98.1</td>
<td>600</td>
</tr>
<tr>
<td>7. C.N.</td>
<td>36</td>
<td>F</td>
<td>154</td>
<td>51</td>
<td>104.9</td>
<td>600</td>
</tr>
<tr>
<td>8. T.T.</td>
<td>55</td>
<td>F</td>
<td>156</td>
<td>53</td>
<td>105.2</td>
<td>600</td>
</tr>
<tr>
<td>9. T.O.</td>
<td>60</td>
<td>F</td>
<td>157</td>
<td>57</td>
<td>111.1</td>
<td>450</td>
</tr>
<tr>
<td>10. H.S.</td>
<td>25</td>
<td>M</td>
<td>169</td>
<td>65</td>
<td>104.7</td>
<td>600</td>
</tr>
</tbody>
</table>

Relative BW, relative body weight = \( \frac{\text{body weight} \times 100}{(\text{height} - 100) \times 0.9} \)
Effect of UDCA on Biliary Bile Acid Composition

and 6 out-patients (4 male and 2 female, aged 36-45) without any gastrointestinal or liver diseases were included in the study.

All patients were informed about the conception of the study and oral consent was obtained.

After an overnight fast, subjects were intubated with a double lumen gastroduodenal tube (Yayoi Co., Tokyo) positioned under fluoroscopic control. 30 ng/kg of Caerulein was injected intravenously for 5 min to elicit the contraction of the gallbladder, and bile rich duodenal content was collected for 10 min by siphonage. This fluid was taken and stored at -20°C until analysis.

**Instrument**

A gas-liquid chromatogram, Hitachi model 056 (Hitachi, Ltd., Tokyo), with a flame ionisation detector was used. The glass U-shaped column (2 m × 3 mm i.d.) was packed with 0.18% Poly-I 110 on Chromosorb WHP (80-100 mesh). The apparatus used for HPLC was a Waters 6000A solvent delivery system (Waters Ass., Milford, Mass.) equipped with a Model Uvidec 100-II ultraviolet (UV) detector monitoring absorbance at 205 nm. A Radial-Pak A column (10 cm × 8 mm i.d., Waters Ass.) was used under ambient conditions.

**Materials**

The unconjugated bile acids were purchased from Sigma Chemical Co. (St. Louis, Mo.) and purified prior to use. The glyco- and tauro-conjugates were synthesized by the p-nitrophenyl ester method in our laboratories. Estriol and UDCA were donated by Teikoku Hormone Mfg. Co. (Tokyo) and Tokyo Tanabe Co. (Tokyo), respectively. All the reagents were of analytical grade. The solvents were purified by distillation prior to use. The trimethylsilylating reagent (TMS-HT) which includes hexamethyldisilazane, trimethylchlorosilane and pyridine, and Sephadex LH-20 were supplied by Tokyo Kasei Co. (Tokyo) and Pharmacia Fine Chemicals (Uppsala), respectively. Piperidinoxypropyl Sephadex LH-20 (PHP-LH-20) and eluents used for ion-exchange gel chromatography were prepared in the manner previously reported (Goto et al. 1978). A Sep-pak C18 cartridge (Water Ass.) was washed successively with methanol (10 ml), acetonitrile (10 ml), and water (10 ml) prior to use (Goto et al. 1980).

**Procedure for determination of bile acids in human bile**

The analysis of bile acids with GLC was carried out by the method of Okawa et al. (1976) with a minor modification (Iwabuchi 1978). After extracting 0.1 ml of duodenal bile with 20-fold ethanol and removing neutral sterol with n-hexane, test samples were subjected to alkaline hydrolysis followed by derivatization with diazomethane and TMS-HT to form TMS ether-methylesters, and then injected into GLC. Temperature of the injector and detector was 260°C. The flow rate of He was 60 ml/min. On this condition

### with UDCA and the efficacy of UDCA

<table>
<thead>
<tr>
<th>Duration (month)</th>
<th>Number of stones</th>
<th>Size of stone (mm)</th>
<th>Floating</th>
<th>Dissolved effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>13</td>
<td>1</td>
<td>13×15</td>
<td>(-)</td>
<td>Smaller</td>
</tr>
<tr>
<td>12</td>
<td>2</td>
<td>4×6, 5×7</td>
<td>(-)</td>
<td>Dissolved</td>
</tr>
<tr>
<td>10</td>
<td>2</td>
<td>2×3, 7×9</td>
<td>(-)</td>
<td>Dissolved</td>
</tr>
<tr>
<td>5</td>
<td>&gt;10</td>
<td>1.5×3</td>
<td>(+)</td>
<td>Dissolved</td>
</tr>
<tr>
<td>28</td>
<td>&gt;10</td>
<td>4×4×14×15</td>
<td>(-)</td>
<td>Dissolved</td>
</tr>
<tr>
<td>12</td>
<td>1</td>
<td>15×22</td>
<td>(-)</td>
<td>Unchanged</td>
</tr>
<tr>
<td>10</td>
<td>&gt;10</td>
<td>2×3×3×5×6</td>
<td>(+)</td>
<td>Smaller</td>
</tr>
<tr>
<td>3</td>
<td>&gt;10</td>
<td>7×10×15×21</td>
<td>(-)</td>
<td>Unchanged</td>
</tr>
<tr>
<td>6</td>
<td>3</td>
<td>12×17</td>
<td>(-)</td>
<td>Unchanged</td>
</tr>
</tbody>
</table>
5β-cholanic acid as an internal standard appeared at 12 min and each bile acids were efficiently resolved. Group separation into free, glycine- and taurine-conjugated bile acids which were submitted to GLC was also achieved by thin-layer chromatography (TLC), as described in the previous papers (Hofmann 1962; Iwabuchi 1968).

The analysis of bile acids with HPLC was carried out by the method previously reported (Goto et al. 1978, 1980). The general procedure for determination of bile acids in human bile is shown in Fig. 1. A bile sample (10 µl) was submitted to clean-up using Sep-pak C18 cartridge and PHP-LH-20 and then to HPLC. The amount of each bile acid was determined by the calibration curve constructed by plotting the ratio of peak area of bile acid to that of estriol against the weight of bile acid. Fig. 2 shows a typical chromatogram of the glycine-conjugated fraction in human bile processed as described above. Lithocholate was not detected on the chromatogram in this specimen.

Total cholesterol was measured by Naka’s method (1972), and phospholipids were assayed as inorganic phosphorus according to Bartlett’s procedure (1959).

Lipid composition of bile was expressed as a “lithogenic index” and calculated from

```
Bile (0.01 ml)
  Sep-Pack C18
  PHP-LH-20
    Neutral Fr.  Free Fr.  Glyco Fr.  Tauro Fr.
      HPLC       HPLC       Sep-Pack C18
                        HPLC
```

Fig. 1. Flow diagram for determination of bile acids in human bile with high performance liquid chromatography.

[Diagram of the flow diagram]

```
Fig. 2. Separation of glycine-conjugated bile acids in human bile by HPLC. Conditions: Radial-Pak A column; detection, ultraviolet (205 nm); mobile phase, (a) 0.3% ammonium phosphate (pH 7.7)/acetonitrile (19:8, v/v), 2 ml/min; (b) 0.3% ammonium phosphate (pH 7.7)/acetonitrile (23:8, v/v), 2 ml/min.
```

[Diagram of the separation chromatograms]
polynomial equation (Thomas and Hofmann 1973) describing the cholesterol solubility line proposed by Admirand and Small (1968).

**Statistical analysis**

All results were expressed as mean values with standard deviations of the mean. The statistical significance of differences between means was estimated using non-paired Student’s *t*-test.

**RESULTS**

*Comparison of analytical results obtained by GLC and HPLC methods*

Comparison of the total amount of bile acids for 25 bile specimens between GLC and HPLC is shown in Fig. 3. An obvious relationship was observed. Each value measured by GLC was lower and represented only 57% of that by HPLC. The ratios of cholate to chenodeoxycholate (C/CDC) and glycine- to taurine-conjugates (G/T) in the two methods were then compared. The results are shown in Figs. 4 and 5. HPLC showed about a 20% higher C/CDC value and a slightly lower G/T value.

![Comparison of total bile acid obtained with high performance liquid chromatography (HPLC) and gas liquid chromatography (GLC).](image)

*Effect of UDCA on gallstone patients*

Examination was made on the dissolution effect of UDCA administration in 10 patients. The complete dissolution of gallstones was observed in 5 patients and the incomplete effect, diminishing of the stone size, was seen in 2 patients. During the UDCA treatment, no change was observed in liver function tests or in the values of fasting serum cholesterol or triglyceride. Neither did the administration of UDCA cause any symptoms, e.g. nausea, abdominal pain, nor symptoms of gastrointestinal irritation including diarrhea.
The lithogenic index lowered significantly in the post-treatment group (0.59±0.14) as compared with the pre-treatment group (1.18±0.71). Changes of lithogenic index in 5 patients with gallstone by the administration of UDCA are shown in Fig. 6.

Biliary bile acid compositions in the control, pre-treatment and post-treatment groups determined by HPLC are shown in Tables 2, 3 and 4, and in Figs. 7, 8, 9, 10, 11 and 12.

No differences were observed in any bile acid composition or in C/CDC or G/T ratio between controls and pre-treatment group. However, in the post-treatment group, significantly lower percentages of primary bile acids, both glycine-conjugates

**Table 2. Biliary bile acid composition in the control group**

<table>
<thead>
<tr>
<th></th>
<th>C (%)moles</th>
<th>CDC (%)moles</th>
<th>DC (%)moles</th>
<th>LC (%)moles</th>
<th>UDC (%)moles</th>
<th>C/CDC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total conjugates</td>
<td>34.7±8.0</td>
<td>45.0±10.6</td>
<td>16.1±11.0</td>
<td>0.1±0.2</td>
<td>4.1±3.4</td>
<td>0.83±0.30</td>
</tr>
<tr>
<td>Glycine-conjugates</td>
<td>27.2±8.0</td>
<td>33.2±5.8</td>
<td>13.5±9.4</td>
<td>0.1±0.2</td>
<td>3.6±3.3</td>
<td>0.85±0.31</td>
</tr>
<tr>
<td>Taurine-conjugates</td>
<td>7.5±2.4</td>
<td>11.8±7.5</td>
<td>2.6±2.0</td>
<td>—</td>
<td>0.4±0.9</td>
<td>0.74±0.25</td>
</tr>
<tr>
<td>Glycine/Taurine</td>
<td>4.03±1.67</td>
<td>3.52±1.47</td>
<td>5.35±2.84</td>
<td>—</td>
<td>9.77±6.40</td>
<td>—</td>
</tr>
</tbody>
</table>

Mean±s.d. (n=12).

C, cholate; CDC, chenodeoxycholate; DC, deoxycholate; LC, lithocholate; UDC, ursodeoxycholate.
Effect of UDCA on Biliary Bile Acid Composition

TABLE 3. Biliary bile acid composition in the pre-treatment group

|                  | C   (% moles) | CDC (% moles) | DC (% moles) | LC (% moles) | UDC (% moles) | C/CDC  
|------------------|---------------|---------------|--------------|--------------|---------------|--------
| Total conjugates | 32.2±5.7      | 45.0±11.1     | 18.0±9.1     | 0.3±0.6      | 4.5±3.8       | 0.76±0.24  
| Glycine-conjugates | 23.4±5.0    | 32.3±8.9      | 14.7±8.4     | 0.3±0.6      | 3.5±5.1       | 0.78±0.29  
| Taurine-conjugates | 8.7±3.7     | 12.7±6.1      | 3.3±1.6      | —            | 1.0±1.1       | 0.78±0.38  
| Glycine/Taurine  | 3.31±2.10     | 3.32±2.40     | 4.90±3.59    | —            | 5.11±4.49     |        

Mean±s.d. (n=15),
C, cholate; CDC, chenodeoxycholate; DC, deoxycholate; LC, lithocholate; UDC, ursodeoxycholate.

TABLE 4. Biliary bile acid composition in the post-treatment group

|                  | C   (% moles) | CDC (% moles) | DC (% moles) | LC (% moles) | UDC (% moles) | C/CDC  
|------------------|---------------|---------------|--------------|--------------|---------------|--------
| Total conjugates | 13.0±5.5      | 36.1±3.9      | 17.6±8.3     | 1.5±2.5      | 41.8±13.6     | 0.51±0.23  
| Glycine-conjugates | 10.6±4.7    | 22.3±4.5      | 16.2±7.6     | 1.5±2.5      | 37.6±13.4     | 0.50±0.27  
| Taurine-conjugates | 2.4±1.7     | 3.8±1.8       | 1.5±1.5      | —            | 4.2±3.1       | 0.60±0.27  

Mean±s.d. (n=7),
C, cholate; CDC, chenodeoxycholate; DC, deoxycholate; LC, lithocholate; UDC, ursodeoxycholate.

Fig. 6. Comparison of lithogenic index between the pre-treatment group (Pr) and post-treatment group (Po), including 5 patients whose biles were analyzed both before and after treatment.

and taurine-conjugates, were obtained than those in the control and pre-treatment groups; especially the C/CDC ratio lowered markedly. Significantly high percentages of both conjugated ursodeoxycholate were obtained in the post-treatment group.

No difference was observed in the deoxycholate (DC) composition between the post-treatment group and the other groups. UDCA administration induced a significant difference in G/T ratio of C, CDC, DC and UDC as compared with those in the pre-treatment group and induced a significantly high value of G/T ratio only
Fig. 7. Comparison of biliary bile acids in the control (■), pre-treatment (▲) and post-treatment (▲▲) group. C, cholate; CDC, chenodeoxycholate; DC, deoxycholate; UDC, ursodeoxycholate.

Fig. 8. Comparison of biliary glycine-conjugated bile acids in the control (■), pre-treatment (▲) and post-treatment (▲▲) groups. C, cholate; CDC, chenodeoxycholate; DC, deoxycholate; UDC, ursodeoxycholate.

Fig. 9. Comparison of biliary taurine-conjugated bile acids in the control (■), pre-treatment (▲) and post-treatment (▲▲) groups. C, cholate; CDC, chenodeoxycholate; DC, deoxycholate; UDC, ursodeoxycholate.
Effect of UDCA on Biliary Bile Acid Composition

Total GET ratio showed a significantly high value in post-treatment group (9.1 ± 4.7) as compared with both pre-treatment group (3.5 ± 1.9) (p < 0.001) and the control group (4.1 ± 1.8) (p < 0.005) (Fig. 12).

DISCUSSION

In the present study, the determination of bile acids in human bile was performed by utilizing both GLC and HPLC. The total bile acid value measured by GLC was about 40% lower than that by HPLC.
A few bile samples were determined by using 3α-hydroxy steroid dehydrogenase (EC 1.1.1.50) (3α-HSD) according to the previous report (Iwata and Yamasaki 1964). Since the levels determined by HPLC and 3α HSD were similar, it seems that much bile acid was lost during hydrolysis and/or extraction with ether by GLC.

Since cholic acid (CA) has tri-hydroxyl groups in the molecule and is more polar than other di- and mono-hydroxylated bile acids, it is supposed that the recovery of this compound is lower than other bile acids in the extraction step and the C/CDC ratio becomes lower in GLC than in HPLC. It is known that taurine-conjugates are more strongly adsorbed on silica gel and the extraction of these conjugates from the support results in difficulty. On the other hand, PHP-LH-20, a lipophilic gel, shows no difference in recovery of glycine- and taurine-conjugates because the conjugates are separated by ion exchange chromatography. Consequently, the higher G/T ratio in GLC is observed.

These results show that HPLC is more suitable for the determination of bile acids in biological fluids and may provide more precise knowledge on the metabolic profile of bile acids in patients with gallstone.

The dissolving percentage of UDCA in this study was higher than 40% in the case of non-calcified stones and about 80% in non-calcified floating and medium-sized stones reported by the Tokyo Cooperative Gallstone Study Group (1980).

Although many studies were reported from the viewpoint of bile acid pool size (Fedorowski et al. 1977; Mok et al. 1977; Roda et al. 1979; Salvioli and Salati 1979) and of cholesterol and bile acid synthesis (Maton et al. 1977; Maton and Dowling 1979), the dissolution mechanism by UDCA is still unclear.

Our findings showed HPLC to be a more useful method for examining bile specimens of patients with cholesterol gallstone. The high value of UDC and the low values of cholate and CDC obtained in this study are in agreement with
Igimi et al. (1977) and Carey and Ko (1979) reported that UDC-conjugates may decrease cholesterol solubility and Raicht et al. (1974) suggested that cholate-conjugates may help cholesterol absorption in rats. Based on these reports Ponz de Leon et al. (1980) speculated that UDCA administration induces a high UDC percentage and a low cholate percentage in biliary bile acids, and causes a decrease of dietary cholesterol absorption along with the presence of a large amount of unconjugated bile acid which could also interfere with the solubilization of cholesterol. Consequently the cholesterol absorption reduced by UDCA administration (Ponz de Leon et al. 1980) may cause a reduction of the hepatic cholesterol secretion (Schersten and Lindblad 1979) and a decrease of lithogenic index (Maton et al. 1977; Makino and Nakagawa 1978; Ponz de Leon et al. 1980), since only a small fraction of the biliary cholesterol is newly synthesized in the liver and the major proportion is derived from lipoprotein cholesterol (Schwartz et al. 1978). Furthermore, dietary cholesterol could be responsible for inducing a supersaturated bile (DenBesten et al. 1973).

On the other hand, though UDC has lower solubility of cholesterol than other bile acids (Igimi et al. 1977; Carey and Ko 1979) and the percentage of UDC in biliary bile acid composition increases with the administration of UDCA (Makino and Nakagawa 1978), UDCA treatment causes a dissolution of cholesterol gallstone in human, and in regard of this mechanism Corrigan et al. (1980) proposed a new theory stating that mesophase formation and dispersion may occur during gallstone dissolution in the gallbladder of patients receiving UDCA.

A significantly lower C/ICDC ratio is presented in the post-treatment group than in the other two groups, i.e. the percentage of cholate is lower than that of CDC in the two primary bile acids which are reduced by UDCA administration. Therefore it is also possible to consider that a part of CDC is transformed from UDCA directly (Fedorowski et al. 1979) by intestinal bacteria or by liver enzyme following dehydration with intestinal bacteria (Fedorowski et al. 1977; Fromm et al. 1977). At the same time newly synthesized lithocholate from CDC in the intestine may be excreted into feces or may be detoxified by sulfation in the human liver (Allan et al. 1975).

In the present study no difference was observed in the deoxycholate (DC) composition between the post-treatment group and the other groups. Many authors have reported that the deoxycholate composition decreased by the administration of UDCA (Fedorowski et al. 1977; Makino and Nakagawa 1978; Stiehl et al. 1978; Roda et al. 1979; Ponz de Leon et al. 1980). It is clear that this difference is not dependent on the analytical method since the bile acid compositions in the control or pre-treatment groups of this study are in agreement with those of the pre-treatment group in other reports (Fedorowski et al. 1977; Makino and Nakagawa 1978; Stiehl et al. 1978; Roda et al. 1979; Ponz de Leon et al. 1980). Higher DC concentrations in biliary bile acids are reported to be beneficial
to the cholesterol gallstone dissolution, since DC has higher cholesterol solubility than other bile acids (Hegardt and Dam 1971). The absence of the decrease in the mole percentage in this study may be considered as follows: CDCA treatment is often accompanied with diarrhea which is less frequent under UDCA treatment (Maton et al. 1977). At equimolar concentrations, CDCA induced a more marked inhibitory effect on the colonic absorption of water, sodium and oxalate in the rat (Caspar and Meyne 1980). Debongnie and Phillips (1977) observed that, in humans, under continuous infusion of isotonic solution into caecum, CDC feeding impaired colonic compensation, and UDC feeding did not reduce the capacity of the colon to handle a saline load at all. On the basis of these reports, it is thought that UDCA has only the same stimulation of colonic function as saline feeding has and that the motility of the intestine may be less stimulated by UDCA than CDCA which may stimulate the motility because of the increased intraluminal content (Debongnie and Phillips 1977; Caspar and Meyne 1980). The transit time of intestinal content may not be so shortened by UDCA feeding as compared with no feeding in the colon which is possibly one of the DC producing sites by intestinal bacteria (Miettinen and Peltokallio 1971; Percy-Robb et al. 1971). Consequently mole percent of DC was not changed.

Burnett (1965) reported a slightly lower G/T ratio in patients with gallstone. Our results showed a similar tendency in the pre-treatment group and a significantly higher ratio in the post-treatment group.

Excess conjugation of bile acids may produce a low percentage of taurine-conjugates in the biliary bile acid composition (Danzinger et al. 1973; Hardison 1978). The administered UDCA, absorbed at a rate of about 90% in the intestine (Fedorowski et al. 1977), demands the conjugation along with the endogenous bile acids, and may produce a high G/T ratio (Stiehl et al. 1980; Kanazawa et al. 1980). The G/T ratio of DC is higher than that of the primary bile acids which may be less synthesized in the feed back mechanism by UDCA because of free form of DC which is transformed from cholate with deconjugation and dehydration by intestinal bacteria. This study indicates that the high G/T ratio could play a role in the dissolution mechanism in consideration of previous reports presenting higher solubility of cholesterol in glycine-conjugates than that in taurine-conjugates (Earnest and Admirand 1971; Hegardt and Dam 1971).

In the present study, no difference of DC and a significantly high value of G/T ratio were observed in gallstone patients with the administration of UDCA. However, since the transformation of cholate to deoxycholate is dependent on intestinal bacteria, the relationship between deoxycholate composition and UDCA administration is not clear.

To elucidate the dissolution mechanism, further studies must be done from all angles and more precise knowledge of bile acid metabolism is needed. High-performance liquid chromatography will provide valuable information for this purpose.
References


Effect of UDCA on Biliary Bile Acid Composition


